Nektar Therapeutics (NKTR) Current Leases (2011 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Current Leases of $22.5 million for Q1 2026, up 3.15% year-over-year from $21.8 million in Q1 2025, and up 9.93% quarter-over-quarter from $20.5 million in Q4 2025.
Nektar Therapeutics (NKTR) Current Leases (2011 - 2026) Analysis & Trends
Nektar Therapeutics' Current Leases history runs 14 years deep, the most recent figure standing at $22.5 million for Q1 2026.
- In Q1 2026, Current Leases rose 3.15% year-over-year to $22.5 million; the TTM figure through Mar 2026 stood at $22.5 million (up 3.15% YoY), while the FY2025 annual figure was $20.5 million, up 3.16% from the prior year.
- Current Leases for Q1 2026 stood at $22.5 million, up from $20.5 million in the prior quarter.
- The five-year high for Current Leases was $22.5 million in Q1 2026, with the low at $18.5 million in Q3 2022.
- The 5-year median for Current Leases is $19.9 million (2024), against an average of $20.2 million.
- The sharpest annual moves came in 2022 and 2023: Current Leases advanced 24.28% in 2022, then slipped 5.56% in 2023.
- Nektar Therapeutics' Current Leases stood at $18.7 million in 2022, then advanced by 3.17% to $19.3 million in 2023, then grew by 3.16% to $19.9 million in 2024, then advanced by 3.16% to $20.5 million in 2025, then gained by 9.93% to $22.5 million in 2026.
- Business Quant data shows NKTR's Current Leases at $22.5 million in Q1 2026, $20.5 million in Q4 2025, and $22.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | 22.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.53 Mn |
| Dec 31, 2025 | 20.50 Mn |
| Sep 30, 2025 | 22.18 Mn |
| Jun 30, 2025 | 22.01 Mn |
| Mar 31, 2025 | 21.84 Mn |
| Dec 31, 2024 | 19.87 Mn |
| Sep 30, 2024 | 21.50 Mn |
| Jun 30, 2024 | 21.34 Mn |
| Mar 31, 2024 | 19.37 Mn |
| Dec 31, 2023 | 19.26 Mn |
| Sep 30, 2023 | 19.10 Mn |
| Jun 30, 2023 | 18.93 Mn |
| Mar 31, 2023 | 18.77 Mn |
| Dec 31, 2022 | 18.67 Mn |
| Sep 30, 2022 | 18.51 Mn |
| Jun 30, 2022 | 20.05 Mn |
| Mar 31, 2022 | 19.60 Mn |
| Dec 31, 2021 | 17.44 Mn |
| Sep 30, 2021 | 17.74 Mn |
| Jun 30, 2021 | 16.78 Mn |